Compare CHOW & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHOW | HCWB |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8M | 14.8M |
| IPO Year | N/A | 2021 |
| Metric | CHOW | HCWB |
|---|---|---|
| Price | $0.37 | $1.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 185.3K | ★ 26.0M |
| Earning Date | 06-17-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.37 |
| Revenue | N/A | ★ $4,099,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.80 | ★ $4.41 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.25 |
| 52 Week High | $12.05 | $7.35 |
| Indicator | CHOW | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 40.26 | 53.32 |
| Support Level | $0.34 | $0.56 |
| Resistance Level | $0.52 | $1.90 |
| Average True Range (ATR) | 0.03 | 0.64 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 14.73 | 21.10 |
ChowChow Cloud International Holdings Ltd is providing one-stop cloud solutions that support companies across the IT industry value chain throughout their entire cloud transformation journey from consulting, deployment and migration to cloud environment building and management. Its business comprises (i) digital transformation consulting services consisting of cloud suitability assessment (ii) professional IT services comprising of capabilities designed to facilitate seamless cloud integration and digital transformation, (iii) AI-powered proactive cloud managed services covering all aspects of day-to-day cloud maintenance and support, and (iv) IT infrastructure solutions covering on-premise private cloud setups and public cloud integrations including infrastructure applications.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.